Literature DB >> 19053778

Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41.

Kun Liu1, Hong Lu, Ling Hou, Zhi Qi, Cátia Teixeira, Florent Barbault, Bo-Tao Fan, Shuwen Liu, Shibo Jiang, Lan Xie.   

Abstract

On the basis of the structures of small-molecule hits targeting the HIV-1 gp41, N-(4-carboxy-3-hydroxy)phenyl-2,5-dimethylpyrrole (2, NB-2), and N-(3-carboxy-4-chloro)phenylpyrrole (A(1), NB-64), 42 N-carboxyphenylpyrrole derivatives in two categories (A and B series) were designed and synthesized. We found that 11 compounds exhibited promising anti-HIV-1 activity at micromolar level and their antiviral activity was correlated with their inhibitory activity on gp41 six-helix bundle formation, suggesting that these compounds block HIV fusion and entry by disrupting gp41 core formation. The structure-activity relationship and molecular docking analysis revealed that the carboxyl group could interact with either Arg579 or Lys574 to form salt bridges and two methyl groups on the pyrrole ring were favorable for interaction with the residues in gp41 pocket. The most active compound, N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrrole (A(12)), partially occupied the deep hydrophobic pocket, suggesting that enlarging the molecular size of A(12) could improve its binding affinity and anti-HIV-1 activity for further development as a small-molecule HIV fusion and entry inhibitor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19053778      PMCID: PMC2656571          DOI: 10.1021/jm800869t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  30 in total

1.  Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.

Authors:  Qian Zhao; Liying Ma; Shibo Jiang; Hong Lu; Shuwen Liu; Yuxian He; Nathan Strick; Nouri Neamati; Asim Kumar Debnath
Journal:  Virology       Date:  2005-09-01       Impact factor: 3.616

Review 2.  HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds.

Authors:  Shuwen Liu; Shuguang Wu; Shibo Jiang
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

3.  Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitors.

Authors:  Cátia Teixeira; Florent Barbault; Joseph Rebehmed; Kun Liu; Lan Xie; Hong Lu; Shibo Jiang; BoTao Fan; François Maurel
Journal:  Bioorg Med Chem       Date:  2008-01-28       Impact factor: 3.641

Review 4.  HIV entry and its inhibition.

Authors:  D C Chan; P S Kim
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

5.  A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody.

Authors:  S Jiang; K Lin; L Zhang; A K Debnath
Journal:  J Virol Methods       Date:  1999-06       Impact factor: 2.014

6.  Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1.

Authors:  A K Debnath; L Radigan; S Jiang
Journal:  J Med Chem       Date:  1999-08-26       Impact factor: 7.446

7.  Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.

Authors:  Shuwen Liu; Hong Lu; Jinkui Niu; Yujia Xu; Shuguang Wu; Shibo Jiang
Journal:  J Biol Chem       Date:  2005-01-07       Impact factor: 5.157

8.  Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides.

Authors:  V N Malashkevich; D C Chan; C T Chutkowski; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

9.  Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.

Authors:  Yuxian He; Shuwen Liu; Weiguo Jing; Hong Lu; Dongmei Cai; Darin Jeekin Chin; Asim K Debnath; Frank Kirchhoff; Shibo Jiang
Journal:  J Biol Chem       Date:  2007-07-06       Impact factor: 5.157

10.  SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase.

Authors:  Jay P Powers; Derek E Piper; Yang Li; Veronica Mayorga; John Anzola; James M Chen; Juan C Jaen; Gary Lee; Jinqian Liu; M Greg Peterson; George R Tonn; Qiuping Ye; Nigel P C Walker; Zhulun Wang
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

View more
  28 in total

1.  In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.

Authors:  Zhonghua Liu; Mei Shan; Li Li; Lu Lu; Shu Meng; Cheng Chen; Yuxian He; Shibo Jiang; Linqi Zhang
Journal:  J Biol Chem       Date:  2010-11-23       Impact factor: 5.157

2.  Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.

Authors:  Xiaowen Yu; Lu Lu; Lifeng Cai; Pei Tong; Suiyi Tan; Peng Zou; Fanxia Meng; Ying-Hua Chen; Shibo Jiang
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

3.  Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.

Authors:  M L Bellows; M S Taylor; P A Cole; L Shen; R F Siliciano; H K Fung; C A Floudas
Journal:  Biophys J       Date:  2010-11-17       Impact factor: 4.033

4.  DNA Triplex-Based Complexes Display Anti-HIV-1-Cell Fusion Activity.

Authors:  Liang Xu; Tao Zhang; Xiaoyu Xu; Huihui Chong; Wenqing Lai; Xifeng Jiang; Chao Wang; Yuxian He; Keliang Liu
Journal:  Nucleic Acid Ther       Date:  2015-08       Impact factor: 5.486

5.  Molecular dynamics modeling the synthetic and biological polymers interactions pre-studied via docking: anchors modified polyanions interference with the HIV-1 fusion mediator.

Authors:  Vladimir B Tsvetkov; Alexander V Serbin
Journal:  J Comput Aided Mol Des       Date:  2014-05-27       Impact factor: 3.686

Review 6.  Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.

Authors:  M L Bellows; C A Floudas
Journal:  Curr Drug Targets       Date:  2010-03       Impact factor: 3.465

7.  Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.

Authors:  Yong Wang; Hong Lu; Qiang Zhu; Shibo Jiang; Yun Liao
Journal:  Bioorg Med Chem Lett       Date:  2009-11-05       Impact factor: 2.823

Review 8.  Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.

Authors:  Lu Lu; Fei Yu; Lifeng Cai; Asim K Debnath; Shibo Jiang
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

9.  Synthesis and Anticancer Activity Evaluation of 5-[2-Chloro-3-(4-nitrophenyl)-2-propenylidene]-4-thiazolidinones.

Authors:  Kamila Buzun; Anna Kryshchyshyn-Dylevych; Julia Senkiv; Olexandra Roman; Andrzej Gzella; Krzysztof Bielawski; Anna Bielawska; Roman Lesyk
Journal:  Molecules       Date:  2021-05-20       Impact factor: 4.411

Review 10.  Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection.

Authors:  Jian J Tan; Xiao J Cong; Li M Hu; Cun X Wang; Lee Jia; Xing-Jie Liang
Journal:  Drug Discov Today       Date:  2010-01-22       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.